BRCA1 and breast carcinoma: For example, in phase II trials, 400 mg twice daily exposure of PARPi olaparib only resulted in the delay of breast cancer and ovarian cancer progression (both with median progression-free survival of about six months), and all patients with BRCA1/2 mutations eventually died of cancers [53,54].